Literature DB >> 16830153

A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells.

Takeshi Kawano1, Naoki Agata, Surender Kharbanda, David Avigan, Donald Kufe.   

Abstract

PURPOSE: The isocoumarin NM-3 reverses resistance of human multiple myeloma (MM) cells to dexamethasone and is in clinical trials. In the present work, the NM-3 analog, 185322, has been studied for activity against MM cells.
METHODS: Human U266, RPMI8226 and primary MM cells were analyzed for the effects of 185322 on cell cycle distribution, tubulin polymerization and induction of apoptosis.
RESULTS: We show that, in contrast to NM-3, treatment with 185322 is associated with a marked arrest of MM cells in M phase. The results also demonstrate that treatment with 185322 is associated with a rapid decrease in tubulin assembly and an increase in Bcl-2 phosphorylation, consistent with disruption of mitosis. Our results further demonstrate that mitotic failure induced by 185322 results in activation of an apoptotic response in MM cell lines and primary MM cells. By contrast, 185322 had little if any effect on growth and survival of human carcinoma cells.
CONCLUSION: These findings identify a novel inhibitor of microtubule assembly that induces mitotic arrest and apoptosis of MM cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830153     DOI: 10.1007/s00280-006-0274-x

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Solution-phase synthesis of a diverse isocoumarin library.

Authors:  Sujata Roy; Sudipta Roy; Benjamin Neuenswander; David Hill; Richard C Larock
Journal:  J Comb Chem       Date:  2009 Nov-Dec

2.  PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells.

Authors:  E N Maginn; P V Browne; P Hayden; E Vandenberghe; B MacDonagh; P Evans; M Goodyer; P Tewari; G Campiani; S Butini; D C Williams; D M Zisterer; M P Lawler; A M McElligott
Journal:  Br J Cancer       Date:  2010-12-21       Impact factor: 7.640

3.  New substituted isocoumarins and Dihydroisocoumarins and their cytotoxic activities.

Authors:  Veronika Hampl; Isolde Wetzel; Franz Bracher; Jürgen Krauss
Journal:  Sci Pharm       Date:  2010-12-18

Review 4.  The therapeutic potential of cell cycle targeting in multiple myeloma.

Authors:  Anke Maes; Eline Menu; Kim De Veirman; Ken Maes; Karin Vand Erkerken; Elke De Bruyne
Journal:  Oncotarget       Date:  2017-06-28

5.  Dichloroisocoumarins with Potential Anti-Inflammatory Activity from the Mangrove Endophytic Fungus Ascomycota sp. CYSK-4.

Authors:  Yan Chen; Zhaoming Liu; Hongju Liu; Yahong Pan; Jing Li; Lan Liu; Zhigang She
Journal:  Mar Drugs       Date:  2018-02-09       Impact factor: 5.118

6.  One-pot construction of diverse and functionalized isochromenoquinolinediones by Rh(iii)-catalyzed annulation of unprotected arylamides with 3-diazoquinolinediones and their application for fluorescence sensor.

Authors:  Rajeev Shrestha; Hari Datta Khanal; Yong Rok Lee
Journal:  RSC Adv       Date:  2019-06-03       Impact factor: 3.361

Review 7.  The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies.

Authors:  Taylor Harding; Linda Baughn; Shaji Kumar; Brian Van Ness
Journal:  Leukemia       Date:  2019-01-25       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.